New hope for kids with tough neuroblastoma: blood vessel blocker shows promise
NCT ID NCT02308527
First seen May 12, 2026 · Last updated May 16, 2026 · Updated 1 time
Summary
This study tested whether adding bevacizumab (a drug that cuts off a tumor's blood supply) to standard chemotherapy helps children aged 1 to 21 with neuroblastoma that has come back or not responded to treatment. About 225 children took part. The goal was to see if the combination could shrink tumors or slow the disease. While not a cure, the approach aims to better control the cancer and improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hopital des Enfants
Toulouse, 31059, France
-
Instituto de Investigacion Sanitaria
Valencia, 46026, Spain
-
Natasha van Eijkelenburg
Utrecht, Netherlands
-
Ospedale Pediatrico Bambino Gseu
Rome, 00165, Italy
-
Our Ladys Children's Hospital Dublin
Dublin, Dublin 12, Ireland
-
St Anna Children's Hospital and CCRI/Studies and Statistics
Vienna, A-1090, Austria
-
Swiss Paediatric Oncology Group
Bern, 3008, Switzerland
-
The Royal Marsden NHS Foundation Trust and Institute of Cancer Research
Sutton, Surrey, SM2 5PT, United Kingdom
-
University Hospital
Ghent, Belgium
-
University Hospital Rigshospitalet
Copenhagen, DK-2100, Denmark
Conditions
Explore the condition pages connected to this study.